About this trial
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.
Eligibility criteria
Qualifiers
18 years and older
NT-proBNP > 125 pg/mL
BNP > 35 pg/mL
Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI <2.8 L/min/m2
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Roche Diagnostics GmbH
Collaborator